Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Amortization of Deferred Charges (2022 - 2023)

Werewolf Therapeutics (HOWL) has disclosed Amortization of Deferred Charges for 2 consecutive years, with $60000.0 as the latest value for Q1 2023.

  • Quarterly Amortization of Deferred Charges changed N/A to $60000.0 in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $60000.0 through Dec 2023, down 70.44% year-over-year, with the annual reading at $60000.0 for FY2023, 70.44% down from the prior year.
  • Amortization of Deferred Charges for Q1 2023 was $60000.0 at Werewolf Therapeutics, down from $203000.0 in the prior quarter.
  • The five-year high for Amortization of Deferred Charges was $203000.0 in Q4 2022, with the low at $60000.0 in Q1 2023.